{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-127045","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.634420+00:00","generated_at":"2026-05-30T00:34:04.757701+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tivic Health Q3 revenue $126K, down 27% YoY; net loss narrows to $1.4M","bullets":["Revenue for nine months ended Sep 30, 2024: $600K, down 27% vs 2023 on 36% fewer units sold.","Net loss in Q3 2024 was $1.4M vs $1.8M in Q3 2023; operating expenses cut $1.9M YTD.","Cash at Sep 30: $2.2M; raised $775K net in Oct-Nov via stock sales.","Completed Phase 1a optimization study for non-invasive VNS; partnered with Fletcher Spaght.","Appointed Lisa Wolf as interim CFO effective Oct 1; supply chain redesigned for higher margins."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-127045","json":"https://secwatch.observer/filing/0000950170-24-127045.json","markdown":"https://secwatch.observer/filing/0000950170-24-127045.md","text":"https://secwatch.observer/filing/0000950170-24-127045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000095017024127045/0000950170-24-127045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000095017024127045/tivc-20241114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:34:04.757701+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}